Johnson & Johnson (JNJ) 10-Q2022 Q1 Quarterly report

Filed: 29 Apr 22, 4:08pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	8th grade Avg

New words: abeyance, AD, Adhesive, ahead, Ambulatory, appointed, Atopic, Attune, banc, barrister, billing, buy, Changzhou, Chemical, comparison, conflict, consummate, delivery, directly, disqualify, diversion, downturn, Duato, Elan, EMEA, en, enrollment, Factory, Fort, grantee, HAFYERA, Hawaii, HS, IMODIUM, imposed, inappropriate, intention, invasion, Iowa, Joaquin, LATAM, location, mark, mechanism, MedTech, Michigan, Micro, Minnesota, momentum, month, MSA, Multidistrict, Nebraska, NEOSPORIN, Occidental, outpatient, Passaic, penetration, permission, permitted, PI, pretrial, Rasmussen, reexamination, rehearing, respiratory, River, Russia, Russian, Sizer, SKU, small, standalone, succeed, Superintending, Suppurativa, suspend, SYMTUZA, tape, targeting, Tolmar, treble, Turkey, UC, Ukraine, unlimited, upper, vacate, vast, view, willfully, Wyoming

Removed: Acclarent, adjourned, agent, agree, AHV, Albritton, Alex, alfa, Antibacterial, appealing, ASP, assume, assumed, Atomic, biodegradable, Blue, Brexit, BTG, canton, captioned, causally, CMF, commercialization, Community, compound, cooperation, deal, delayed, dermatological, developmental, DMCC, Education, epoetin, EU, Euratom, exited, Ford, forum, found, GILTI, Gorsky, HMO, implantable, inquiry, institution, Labor, LCC, leadership, learned, Lek, leveraging, licensee, lifting, Madison, Main, MONOCRYL, Murray, Nippon, officially, opposed, ordered, outbreak, overturn, owner, pay, PDS, Personalize, PHS, Planning, political, polymer, Polymorph, positive, procedure, promotional, proof, PROPLAN, reassign, receipt, referendum, referred, rejection, releasing, RELIEVA, RELIEVEA, remeasurement, rescheduled, reversal, schedule, science, Senate, Senator, Sherman, Shield, Shinyaku, significantly, situation, Spin, STRATAFIX, Subcommittee, substitute, sued, Switzerland, TCA, TissueGen, tolling, TRAF, transition, true, TruMatch, UK, unclear, University, UT, Verb, Verily, VICRYL, Virtual, waiving

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

Associated JNJ transcripts

JNJ similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.2

CERTIFICATION OF CHIEF FINANCIAL OFFICER

PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT

The undersigned, Joseph J. Wolk, the Chief Financial Officer of Johnson & Johnson, a New Jersey corporation (the “Company”), pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, hereby certifies that, to the best of my knowledge:

(1)

the Company's Quarterly Report on Form 10-Q for the quarterly period ended April 3, 2022 (the “Report”) fully complies with the requirements of Section 13(a) of the Securities Exchange Act of 1934; and

(2)

the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ Joseph J. Wolk

Joseph J. Wolk

Chief Financial Officer

Dated: April 29, 2022

This certification is being furnished to the SEC with this Report pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by such Act, be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to liability of that section.